Close Menu

Government-performed comparative drug studies are bad because the results not only affect Medicare but the private market as well, writes American Enterprise Institute fellow Scott Gottlieb in an op-ed for the Wall Street Journal. A provision for a new federal center to study the economics of drug choices (part of the State Children's Health Insurance Program) will give misleading results and the data will not be transparent, argues Gottlieb, drawing on past studies such as

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.